Andy Blauvelt, EADV 2021: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis
touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis.
His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp Psoriasis: Analysis of the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.
- Could you tell us a little about deucravacitinib and POETYK PSO-1 and POETYK PSO-2 studies? (0:18)
- What were the efficacy findings from the primary data analysis? (2:14)
- What questions remain unanswered and where do you see deucravacitinib fitting in the treatment of scalp psoriasis? (4:22)
Disclosures: Dr Andy Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Matthew Goodwin.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
Share this Video
Related Videos In Psoriasis
Alan Menter, Dermatology Meeting News 2023: Ixekizumab treatment for patients with moderate-to-severe plaque psoriasis
Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a post-hoc analysis conducted on trials studying the use of ixekizumab in adult and paediatric patients […]
Alan Menter, Dermatology Meeting News 2023: Clinical presentations and unmet needs of palmoplantar psoriasis
Palmoplantar psoriasis has a significant impact on patients’ quality of life and can be challenging to treat. touchIMMUNOLOGY were delighted to speak with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA), about the prevalence and clinical presentations of palmoplantar psoriasis, its impact on quality of life, and the unmet needs in its treatment. […]
Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis
Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY were delighted to speak with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!